Should You Buy It? Impax Labs By David Peltier About this article: Generic drugmaker Impax Laboratories appears to be flying under the market radar. On Tuesday, the company posted third-quarter earnings of 11 cents a share, handily exceeding the consensus analyst estimate of 5 cents a share. Revenue also grew 77% year over year to $64.9 million. Even so, at Wednesday's closing price of $9.42, the stock is lagging the broader market averages, up just 8% year-to-date. With that in mind, I'm here to answer readers' questions: Should you buy it? Does Impax offer value at current levels, or should investors focus elsewhere? Wednesday was the first anniversary of President Obama's election victory, which is relevant because the generic drug space has steadily been gaining mindshare ever since. While no health care bill has been passed by Congress to date, there's little denying that generic medicines are a quick way to lower expenses for patients. The newest driver for Impax is... Or, call us at 1-866-321-TSCM (8726) Monday-Friday, 8 a.m.-6 p.m. ET. Outside the U.S. and in Canada, call 1-212-321-5200. More Stories From RealMoney Durable Goods Up Move Down the Tech Food Chain Jobless Claims Still High Bulls' Tenacity Is the Big Question Mark Should You Buy It? Pharmaceutical Product Development Bad News Trumps All Support for Banks Holds, For Now Bummer, Yields Are on the Rise Money on the Line Makes a Big Difference Structured Products: Unsafe at Any Price MORE STORIES FROM REALMONEY

If you choose a 14-day free trial of RealMoney and you do NOT call to cancel within those 14 days, you will pay $129.95 — a $100 savings off the regular annual subscription price of $229.95. Unless you cancel before the end of that year, your subscription will automatically renew for another year at the then-current subscription price.

Offer applies only to new annual subscriptions, and is subject to change at any time. Void where prohibited.

If you choose a monthly subscription, you pay $34.95 per month. You will be notified if the current monthly rate of $34.95 changes at any time in the future.

TheStreet.com is a publisher. None of the contributors or their affiliates will provide you with personally tailored advice concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. From time to time, any or all of the contributors or their affiliates may hold positions in securities mentioned and they may trade for their own accounts. In cases where the position is held at the time of publication, appropriate disclosure is made.

© TheStreet.com, Inc., 14 Wall Street, 15th Floor, New York, NY 10005.